Standard therapy for HIV-related Hodgkin lymphoma (HIV-HL) has not been defined. This trial
was initiated to investigate a risk adapted treatment strategy in patients (pts) with HIV-HL
as established in HIV-negative patients with HL.
Treatment schedule:
- Early stage favorable Hodgkin Lymphoma (HL): 2 cycles of doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD) plus 30 Gy involved field (IF) radiation
- Early stage unfavorable HL: 4 cycles of bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline or 4
cycles of ABVD plus 30 Gy IF radiation
- Advanced HL: 8 cycles of BEACOPP-baseline. BEACOPP should be replaced by ABVD in pts
with far advanced HIV-infection. After the completion of chemotherapy sites of initial
bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in
diameter receive 30 Gy of irradiation.
- Primary outcome measure: tolerability, treatment-related mortality
- Secondary outcome measure: complete remission rate, progression-free survival (PFS),
overall survival (OS).